A PHASE IV, RANDOMISED, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE IMPACT ON DISEASE CONTROL, SAFETY, PATIENT AND CLINICIAN EXPERIENCE OF CHANGING PATIENTS WITH ADVANCED PROSTATE CANCER FROM A 3-MONTHLY LHRH AGONIST TO 6-MONTHLY INJECTIONS OF DECAPEPTYL SR 22.5 MG
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2015
At a glance
- Drugs Triptorelin (Primary) ; Goserelin; Leuprorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms GREAT
- Sponsors Ipsen
- 10 Jun 2017 Biomarkers information updated
- 28 Sep 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 29 Apr 2014 According to the ClinicalTrials.gov reciord, status changed from active, no longer recruiting to completed.